Literature DB >> 19698077

Antibody responses in oral fluid after administration of prophylactic human papillomavirus vaccines.

Ali Rowhani-Rahbar1, Joseph J Carter, Stephen E Hawes, James P Hughes, Noel S Weiss, Denise A Galloway, Laura A Koutsky.   

Abstract

We sought to determine whether oral fluid can be used to assess serum human papillomavirus (HPV) antibody status by enrolling women who had received a prophylactic HPV-16 vaccine in a new follow-up study. After the prophylactic HPV-6/11/16/18 vaccine was licensed in the United States, we administered it to consenting participants. With serologic findings used as the reference standard, The sensitivity of oral fluid was 49.6% (95% confidence interval [CI], 42.0%-57.3%) before and 100% (95% CI, 92.0%-100%) after administration of the quadrivalent vaccine. Oral fluid may have the potential to be used for monitoring of prophylactic HPV vaccines in the future.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19698077      PMCID: PMC3392559          DOI: 10.1086/606026

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Has oral fluid the potential to replace serum for the evaluation of population immunity levels? A study of measles, rubella and hepatitis B in rural Ethiopia.

Authors:  D J Nokes; F Enquselassie; W Nigatu; A J Vyse; B J Cohen; D W Brown; F T Cutts
Journal:  Bull World Health Organ       Date:  2001       Impact factor: 9.408

2.  Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial.

Authors:  Constance Mao; Laura A Koutsky; Kevin A Ault; Cosette M Wheeler; Darron R Brown; Dorothy J Wiley; Frances B Alvarez; Oliver M Bautista; Kathrin U Jansen; Eliav Barr
Journal:  Obstet Gynecol       Date:  2006-01       Impact factor: 7.661

3.  Suppression of non-specific binding in serological Luminex assays.

Authors:  Tim Waterboer; Peter Sehr; Michael Pawlita
Journal:  J Immunol Methods       Date:  2005-12-19       Impact factor: 2.303

4.  The use of the OraSure collection device for hepatitis virus testing in health care settings.

Authors:  Sheila O Cameron; William F Carman
Journal:  J Clin Virol       Date:  2005-12       Impact factor: 3.168

5.  A comparative study of saliva and OraSure oral fluid.

Authors:  M L Cordeiro; C S Turpin; S A McAdams
Journal:  Ann N Y Acad Sci       Date:  1993-09-20       Impact factor: 5.691

6.  Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins.

Authors:  Tim Waterboer; Peter Sehr; Kristina M Michael; Silvia Franceschi; John D Nieland; Thomas O Joos; Markus F Templin; Michael Pawlita
Journal:  Clin Chem       Date:  2005-08-11       Impact factor: 8.327

7.  Future applications of oral fluid specimen technology.

Authors:  J R George; J H Fitchen
Journal:  Am J Med       Date:  1997-04-01       Impact factor: 4.965

8.  Oral antibodies to human papillomavirus type 16 in women with cervical neoplasia.

Authors:  D J Marais; J M Best; R C Rose; P Keating; R Soeters; L Denny; C M Dehaeck; J Nevin; P Kay; J A Passmore; A L Williamson
Journal:  J Med Virol       Date:  2001-09       Impact factor: 2.327

9.  Comparison of oral fluid and serum ELISAs in the determination of IgG response to natural human papillomavirus infection in university women.

Authors:  Farrel J Buchinsky; Joseph J Carter; Gregory C Wipf; James P Hughes; Laura A Koutsky; Denise A Galloway
Journal:  J Clin Virol       Date:  2005-11-28       Impact factor: 3.168

10.  Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals.

Authors:  Jennifer E Cameron; Isaac V Snowhite; Anil K Chaturvedi; Michael E Hagensee
Journal:  Clin Diagn Lab Immunol       Date:  2003-05
View more
  17 in total

1.  Serum antibody response following genital {alpha}9 human papillomavirus infection in young men.

Authors:  Zoe R Edelstein; Joseph J Carter; Ruchi Garg; Rachel L Winer; Qinghua Feng; Denise A Galloway; Laura A Koutsky
Journal:  J Infect Dis       Date:  2011-07-15       Impact factor: 5.226

Review 2.  The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer.

Authors:  Theresa Guo; David W Eisele; Carole Fakhry
Journal:  Cancer       Date:  2016-05-06       Impact factor: 6.860

Review 3.  Emerging human papillomavirus vaccines.

Authors:  Barbara Ma; Bharat Maraj; Nam Phuong Tran; Jayne Knoff; Alexander Chen; Ronald D Alvarez; Chien-Fu Hung; T-C Wu
Journal:  Expert Opin Emerg Drugs       Date:  2012-11-19       Impact factor: 4.191

4.  Analysis of liquid bead microarray antibody assay data for epidemiologic studies of pathogen-cancer associations.

Authors:  Danny V Colombara; James P Hughes; Andrea N Burnett-Hartman; Stephen E Hawes; Denise A Galloway; Stephen M Schwartz; Roberd M Bostick; John D Potter; Lisa E Manhart
Journal:  J Immunol Methods       Date:  2015-06-11       Impact factor: 2.303

5.  Active squamous metaplasia of the cervical epithelium is associated with subsequent acquisition of human papillomavirus 16 infection among healthy young women.

Authors:  Loris Y Hwang; Yifei Ma; Stephen C Shiboski; Sepideh Farhat; Janet Jonte; Anna-Barbara Moscicki
Journal:  J Infect Dis       Date:  2012-06-13       Impact factor: 5.226

6.  Prophylactic immunization with human papillomavirus vaccines induces oral immunity in mice.

Authors:  Julie Ahn; Shiwen Peng; Chien-Fu Hung; Richard B S Roden; Simon R Best
Journal:  Laryngoscope       Date:  2017-09-04       Impact factor: 3.325

7.  Redetection of cervical human papillomavirus type 16 (HPV16) in women with a history of HPV16.

Authors:  Anna-Barbara Moscicki; Yifei Ma; Sepideh Farhat; Teresa M Darragh; Michael Pawlita; Denise A Galloway; Stephen Shiboski
Journal:  J Infect Dis       Date:  2013-04-18       Impact factor: 5.226

8.  Evaluation of HPV-16 and HPV-18 specific antibody measurements in saliva collected in oral rinses and merocel® sponges.

Authors:  Katherine H Parker; Troy J Kemp; Yuanji Pan; Zhen Yang; Anna R Giuliano; Ligia A Pinto
Journal:  Vaccine       Date:  2018-04-06       Impact factor: 3.641

9.  Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children.

Authors:  Adriana Weinberg; Lin-Ye Song; Alfred Saah; Martha Brown; Anna B Moscicki; William A Meyer; Janine Bryan; Myron J Levin
Journal:  J Infect Dis       Date:  2012-08-02       Impact factor: 5.226

10.  Head and neck cancer in Australia between 1982 and 2005 show increasing incidence of potentially HPV-associated oropharyngeal cancers.

Authors:  J S Hocking; A Stein; E L Conway; D Regan; A Grulich; M Law; J M L Brotherton
Journal:  Br J Cancer       Date:  2011-02-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.